News & Views | Published:


New options to treat influenza B

Influenza B virus causes substantial illness globally, particularly in children. Treatment options are limited, as the most widely used antiviral drug appears to be less effective than against influenza A. A new antibody targeting the influenza B neuraminidase shows promise in mice as a therapeutic option.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Rolfes, M. et al. Estimated Influenza Illnesses, Medical Visits, Hospitalizations, and Deaths Averted by Vaccination in the United States (CDC, 2016).

  2. 2.

    Lafond, K. E. et al. PLoS Med. 13, e1001977 (2016).

  3. 3.

    Paul Glezen, W., Schmier, J. K., Kuehn, C. M., Ryan, K. J. & Oxford, J. Am. J. Public Health. 103, e43–e51 (2013).

  4. 4.

    Tran, D. et al. Pediatrics (2016).

  5. 5.

    Wohlbold, T. J. et al. Nat. Microbiol. (2017).

  6. 6.

    Sugaya, N. et al. Clin. Infect. Dis. 44, 197–202 (2017).

  7. 7.

    Kallewaard, N. L. et al. Cell 166, 596–608 (2016).

  8. 8.

    Muthuri, S. G. et al. Lancet Respir. Med. 2, 395–404 (2014).

Download references

Author information

Correspondence to Kanta Subbarao.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark
Fig. 1: Roles of viral neuraminidase and anti-neuraminidase monoclonal antibodies in influenza virus infection.